Friday, March 31, 2023
- 4:30PM-5:00PM
-
Abstract Number: 039
Towards the Definition of Cutoff Values for Disease Activity States in Systemic JIA Using the Systemic Juvenile Arthritis Disease Activity Score
Poster Breakout 6 - Systemic JIA: Genomics, Transcriptomics & Disease States- 4:30PM-5:00PM
-
Abstract Number: 037
Transcriptional Analysis of CD14+ Monocytes During Macrophage Activation Syndrome Highlights Role for Interferons and RNA Sensing in Monocytes
Poster Breakout 6 - Systemic JIA: Genomics, Transcriptomics & Disease States- 5:00PM-6:00PM
-
Abstract Number: 117
A Descriptive Study of Patients with Multisystem Inflammatory Syndrome in Children
Posters: Clinical and Therapeutic II- 5:00PM-6:00PM
-
Abstract Number: 091
Achieving Remission in Childhood-onset Systemic Lupus Erythematosus: Rapid Implementation of an EMR-integrated Dashboard to Measure Disease Activity and Remission Rates
Posters: Clinical and Therapeutic II- 5:00PM-6:00PM
-
Abstract Number: 112
Adverse Childhood Experiences: Prevalence and Relationship to Disease in Childhood-onset Lupus
Posters: Clinical and Therapeutic II- 5:00PM-6:00PM
-
Abstract Number: 133
An Interdisciplinary Team Approach to Implementation of a Social Determinants of Health Screener for Pediatric Rheumatology Patients
Posters: Quality, Health Services, and Education II- 5:00PM-6:00PM
-
Abstract Number: 135
Assessing Medication Adherence in JIA: Pilot Phase Results from a Single-Center Quality Improvement Initiative
Posters: Quality, Health Services, and Education II- 5:00PM-6:00PM
-
Abstract Number: 105
Awareness of Multisystem Inflammatory Syndrome in Children Among U.S. Parents: A Cross-Sectional Survey
Posters: Clinical and Therapeutic II- 5:00PM-6:00PM
-
Abstract Number: 106
Caregivers’ Perspectives on Barriers to Care in Juvenile Localized and Systemic Scleroderma
Posters: Clinical and Therapeutic II- 5:00PM-6:00PM
-
Abstract Number: 098
Characterization of Pulmonary Nodules in Juvenile-onset Systemic Sclerosis: A Single Center Case-Series
Posters: Clinical and Therapeutic II- 5:00PM-6:00PM
-
Abstract Number: 116
Clinical Significance of Anti-Scl-70 Antibodies in Pediatric Lupus Patients: A Single Center Cohort
Posters: Clinical and Therapeutic II- 5:00PM-6:00PM
-
Abstract Number: 114
Clinical Significance of SSA and SSB Antibodies in Pediatric SLE Patients: A Single Center Cohort
Posters: Clinical and Therapeutic II- 5:00PM-6:00PM
-
Abstract Number: 103
Clinical, Serologic, and Imaging Findings of Rhupus Syndrome in the Pediatric Population: A Systematic Literature Review
Posters: Clinical and Therapeutic II- 5:00PM-6:00PM
-
Abstract Number: 093
Comparison Between Induction with Rituximab and Cyclophosphamide in Treatment of Childhood-Onset ANCA-Associated Vasculitis
Posters: Clinical and Therapeutic II- 5:00PM-6:00PM
-
Abstract Number: 096
DADA2 – a Case Series from North India